表紙
市場調查報告書

全球非酒精性脂肪性肝炎(NASH)治療藥物市場:COVID-19潛在影響的見解和預測(2020-2029)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)

出版商 Koncept Analytics 商品編碼 948344
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
全球非酒精性脂肪性肝炎(NASH)治療藥物市場:COVID-19潛在影響的見解和預測(2020-2029) Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)
出版日期: 2020年07月09日內容資訊: 英文 102 Pages
簡介

2029年,全球非酒精性脂肪性肝炎(NASH)治療市場規模達到843.4億美元。在2018年至2029年的預測期內,市場預計將以39.13%的複合年增長率增長。諸如醫療保健支出增加,藥物研發支出增加,糖尿病人口急劇增加,肥胖人口增長,潛在需求以及久坐的生活方式等因素預計將推動市場增長。但是,頑固的藥物批准程序,高昂的治療成本以及NASH/NAFLD診斷的確定性低是市場上的挑戰。市場上的顯著趨勢包括主要NASH藥物的快速市場滲透,NASH流行率的提高,NASH診斷和生物標誌物的發展,NASH管道藥物的開發以及電子商務藥物的銷售增加。

本報告按市場增長因素,挑戰,趨勢和發展,COVID-19的影響,藥物類型和地區來調查非酒精性脂肪性肝炎(NASH)治療的全球市場。我們提供諸如市場分析,競爭狀況和主要公司簡介之類的信息。

內容

第1章市場概述

  • 簡介
  • 原因和症狀
  • 診斷
  • 處理
  • 標籤外處理
  • 治療性治療

第2章COVID-19的影響

  • COVID-19病例數增加
  • 政府增加醫療費用
  • 增加生物標誌物的應用
  • NASH治療劑對臨床試驗的影響

第3章世界市場

  • 按銷售量預測的市場
  • 銷售(預測):按藥品類別
  • 按銷售分類的藥品

第4章全球治療□□藥物市場

  • 銷售預測
  • 按藥物類型劃分的市場銷售預測
    • 2024年的預測
    • 2029年的預測
    • 奧貝膽酸(OCA)按銷售額
    • 奧貝膽酸(OCA)按地區
    • Cenicriviroc(CVC)按銷售額
    • Cenicriviroc(CVC)按地區
    • Elafibranor按銷售額
    • Aramchol:按銷售額
    • MGL-3196:按銷售額
    • INN-217:按銷售額
    • VK2809:按銷售額
  • 按地區劃分的市場銷售預測
    • 2024年的預測
    • 2029年的預測

按地區劃分的第五章市場預測

  • 美國
  • 歐洲
  • 其他地區

第6章市場動態

  • 生長因子
    • 醫療保健支出增加
    • 藥品研發費用增加
    • 糖尿病人口正在迅速增加
    • 肥胖人口增加
    • 未滿足的醫療需求
    • 不動身體的生活
  • 主要趨勢與發展
    • 主要NASH藥物迅速進入市場
    • NASH患病率上升
    • 持續的NASH診斷方法和生物標誌物
    • NASH管道藥物正在開發中
    • 電子商務藥品銷售增長
  • 挑戰
    • 藥品審批流程
    • 治療費用高
    • 相關業務風險
    • NASH/NAFLD的非確定性診斷方法

第7章競爭情況

  • 世界市場
    • 主要公司:收入比較
    • 主要公司:市值比較
    • 主要公司:研發比較
    • 公司:產品組合比較

第8章公司簡介

  • Bristol Myers Squibb
  • Gilead Sciences, Inc.
  • Allergan (Abbvie)
  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals
  • Genfit SA
目錄

The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales.

The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:

The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.

The major regional markets (the U.S., Europe and Rest of World) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.

Key Target Audience:

  • NAFLD/NASH Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Causes & Symptoms
  • 1.3. Diagnosis
  • 1.4. Treatment
  • 1.5. Off-Label Treatment
  • 1.6. Therapeutic Treatment

2. Impact of COVID-19

  • 2.1. Rise in Number of COVID-19 Cases
  • 2.2. Growth in Government Spending on Healthcare
  • 2.3. Rise in Application of Biomarkers
  • 2.4. Impact on NASH Therapeutics Clinical Trials

3. Global NASH Market

  • 3.1. Global NASH Drugs Market Forecast by Value
  • 3.2. Global NASH Drugs Market Value Forecast by Drug Class
  • 3.3. Global NASH Off-Label Drugs Market Forecast by Value

4. Global NASH Therapeutics Market

  • 4.1. Global NASH Therapeutics Market Forecast by Value
  • 4.2. Global NASH Therapeutics Market Value Forecast by Drug Type
    • 4.2.1. Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
    • 4.2.2. Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
    • 4.2.3. Global Obeticholic Acid (OCA) Drug Market Forecast by Value
    • 4.2.4. Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region
    • 4.2.5. Global Cenicriviroc (CVC) Drug Market Forecast by Value
    • 4.2.6. Global Cenicriviroc (CVC) Drug Market Value Forecast by Region
    • 4.2.7. Global Elafibranor Drug Market Forecast by Value
    • 4.2.8. Global Aramchol Drug Market Forecast by Value
    • 4.2.9. Global MGL-3196 Drug Market Forecast by Value
    • 4.2.10. Global INN-217 Drug Market Forecast by Value
    • 4.2.11. Global VK2809 Drug Market Forecast by Value
  • 4.3. Global NASH Therapeutics Market Value Forecast by Region
    • 4.3.1. Global NASH Therapeutics Market Value Forecast by Region (2024)
    • 4.3.2. Global NASH Therapeutics Market Value Forecast by Region (2029)

5. Regional NASH Market

  • 5.1. The U.S. NASH Therapeutics Market Forecast by Value
  • 5.2. Europe NASH Therapeutics Market Forecast by Value
  • 5.3. ROW NASH Therapeutics Market Forecast by Value

6. Market Dynamics

  • 6.1. Growth Drivers
    • 6.1.1. Rising HealthCare Expenditure
    • 6.1.2. Increase in Pharmaceutical R&D Expenditures
    • 6.1.3. Surging Diabetic Population
    • 6.1.4. Escalating Obese Population
    • 6.1.5. Unmet Medical Needs
    • 6.1.6. Sedentary Lifestyle
  • 6.2. Key Trends & Development
    • 6.2.1. Surging Market Penetration for Major NASH Drugs
    • 6.2.2. Increasing Prevalence of NASH
    • 6.2.3. Progressing NASH Diagnosis Methods and Biomarkers
    • 6.2.4. NASH Pipeline Drugs Under Development
    • 6.2.5. Growth in E-Commerce Pharmaceutical Products Sales
  • 6.3. Challenges
    • 6.3.1. Lethargic Drug Approval Process
    • 6.3.2. High Treatment Cost
    • 6.3.3. Associated Business Risk
    • 6.3.4. Less Definitive Diagnostic Methods for NASH/NAFLD

7. Competitive Landscape

  • 7.1. Global NASH Drugs Market
    • 7.1.1. Key Players - Revenue Comparison
    • 7.1.2. Key Players - Market Cap Comparison
    • 7.1.3. Key Players - R&D Comparison
    • 7.1.4. Key Players - Product Portfolio Comparison

8. Company Profiles

  • 8.1. Bristol Myers Squibb
    • 8.1.1. Business Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Business Strategies
  • 8.2. Gilead Sciences, Inc.
    • 8.2.1. Business Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Strategies
  • 8.3. Allergan (Abbvie)
    • 8.3.1. Business Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Strategies
  • 8.4. Intercept Pharmaceuticals, Inc.
    • 8.4.1. Business Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Business Strategies
  • 8.5. Galmed Pharmaceuticals
    • 8.5.1. Business Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Business Strategies
  • 8.6. Genfit SA
    • 8.6.1. Business Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Business Strategies

List of Figures

  • NAFLD Spectrum and Estimated Advancement Risk
  • Treatment of NASH
  • Potential Phase III NASH Drugs
  • Global Government Share on Health Spending (2019-2024)
  • Global Biomarkers Market Value Forecast (2016-2021)
  • Global NASH Drugs Market Forecast by Value (2018-2029)
  • Global NASH Drugs Market Value Forecast by Drug Class (2019/2024/2029)
  • Global NASH Off-Label Drugs Market Forecast by Value (2018-2029)
  • Global NASH Therapeutics Market Forecast by Value (2020-2029)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
  • Global Obeticholic Acid (OCA) Drug Market Forecast by Value (2020-2029)
  • Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region (2029)
  • Global Cenicriviroc (CVC) Drug Market Forecast by Value (2020-2029)
  • Global Cenicriviroc (CVC) Drug Market Value Forecast by Region (2029)
  • Global Elafibranor Drug Market Forecast by Value (2020-2029)
  • Global Aramchol Drug Market Forecast by Value (2022-2029)
  • Global MGL-3196 Drug Market Forecast by Value (2023-2029)
  • Global INN-217 Drug Market Forecast by Value (2023-2029)
  • Global VK2809 Drug Market Forecast by Value (2023-2029)
  • Global NASH Therapeutics Market Value Forecast by Region (2024)
  • Global NASH Therapeutics Market Value Forecast by Region (2029)
  • The U.S. NASH Therapeutics Market Forecast by Value (2022-2029)
  • Europe NASH Therapeutics Market Forecast by Value (2022-2029)
  • ROW NASH Therapeutics Market Forecast by Value (2022-2029)
  • Global HealthCare Expenditure Per Capita (2014-2019)
  • Global Pharmaceutical R&D Expenditures (2014-2019)
  • Global Prevalence of Diabetes (2014-2019)
  • Global Obese Patient Population (2014-2019)
  • Number of NASH Patients treated with Ocaliva and Selonsertib Forecast (2020-2025)
  • The US NASH Patient Population (2018-2028)
  • Global E-Commerce Pharmaceutical Products Sales (2018-2023)
  • Drugs Approval Process
  • Bristol Myers Squibb Total Revenue and Net Earnings (2015-2019)
  • Bristol Myers Squibb Revenue by Segment (2019)
  • Bristol Myers Squibb Revenue by Region (2019)
  • Gilead Sciences Revenue and Net Income (2015-2019)
  • Gilead Sciences Revenue by Segment (2019)
  • Gilead Sciences Revenue by Region (2019)
  • Allergan Plc. (Abbvie) Net Revenue and Net Loss (2015-2019)
  • Allergan Plc. (Abbvie) Net Revenue by Segment (2019)
  • Intercept Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Intercept Pharmaceuticals Revenue by Segment (2019)
  • Galmed Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Genfit SA Revenue and Net Loss (2015-2019)

List of Tables

  • NASH Off-Label Therapies
  • Total Confirmed COVID-19 Cases Worldwide (2020)
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2019)
  • Drugs under Development for NASH (2019)
  • NASH Annual Treatment Cost Comparison (2019)
  • Key Players - Revenue Comparison (2019)
  • Key Players - Market Cap Comparison (2020)
  • Key Players - R&D Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Intercept Pharmaceuticals Product Pipeline (2019)
  • Genfit SA Product Pipeline (2019)